Skip to main content
MainBoardListed
Concord Biotech Limited Logo

Concord Biotech Limited IPO

Concord Biotech Limited IPO

IPO Date :
Issue Price :
Allotment Date :
Listing Date :
List Price :
Lot Size:
Subscription:
Listed Price: ₹ 900.05 (+21.46%)

Concord Biotech Limited's achieved publicly listed status following its IPO debut on 18-08-2023 at the NSE, BSE platform. The offering successfully mobilized 2,09,25,652 Shares, with TBD allocated to corporate growth initiatives and ₹1551.00 Cr providing liquidity to existing shareholders.

Investment participation occurred within the established price band of ₹705 to ₹741, starting from minimum lots of 20 shares. The subscription window from 04-08-2023 through 08-08-2023 enabled investor participation across market segments.

Share allocation was completed on 14-08-2023, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.

Concord Biotech IPO Details
Lot(s) Distribution

Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.

IPO Reservation
Concord Biotech IPO Key Performance Indicator
Company Financials ( In Crores )

Concord Biotech IPO About Company

Incorporated in 1984, Concord Biotech Limited is an India-based biopharmaceutical company and a leading global developer and manufacturer of fermentation-based APIs, specializing in immunosuppressants and oncology. The company has a strong global presence, supplying products to over 70 countries including the USA, India, Europe, and Japan. Concord Biotech manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Starting with a single product, the company has expanded to offer a broad spectrum of biopharma solutions, establishing itself as a key player in the global API market.


Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."


Concord Biotech IPO Strength Factors

NA


Concord Biotech IPO Risk Factors

NA


Concord Biotech IPO Lead Manager(s)

  • Kotak Mahindra Capital Company Limited
  • Citigroup Global Markets India Private Limited
  • Jefferies India Private Limited

Concord Biotech IPO Promoter(s)

  1. Mr. Sudhir Vaid
  2. Mr. Ankur Vaid

Concord Biotech IPO Company Details

Concord Biotech Limited
Phone:
address:

Concord Biotech IPO Registrar

Link Intime India Private Limited
Name:
Phone:

Concord Biotech IPO FAQs